Skip to main content
ARDELYX, INC. logo

ARDELYX, INC. — Investor Relations & Filings

Ticker · ARDX ISIN · US0396971071 LEI · 549300F542QR4SXHCY32 US Manufacturing
Open in API
Filings indexed 1,078 across all filing types
Latest filing 2016-06-07 Director's Dealing
Country US United States of America
Listing US ARDX

About ARDELYX, INC.

https://www.ardelyx.com/

Ardelyx, Inc. is a biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines to address unmet medical needs. The company's primary therapeutic areas of focus are cardiorenal and gastrointestinal diseases. Its key commercial product is XPHOZAH® (tenapanor), a novel mechanism therapy for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Ardelyx also develops treatments for Irritable Bowel Syndrome with Constipation (IBS-C), aiming to advance patient care through its portfolio of innovative therapies.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2016-06-07 English
FORM 4
Director's Dealing
2016-06-07 English
FORM 4
Director's Dealing
2016-06-07 English
FORM 3
Director's Dealing
2016-06-07 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated June 2, 2016, by Ardelyx, Inc. The key content is the submission of matters to a vote at the Annual Meeting of Stockholders, including election of directors and ratification of the independent registered accounting firm. The document provides detailed voting results for these proposals. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. The document is not an Annual Report, Proxy Statement, or Management Report, but specifically reports voting outcomes. The document length is 3425 characters, which is consistent with a voting results announcement rather than a full report or presentation.
2016-06-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company announced its financial results for the first quarter ended March 31, 2016, and that the full text of the press release is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references a press release. The length of the document is 2671 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, if a document is short and announces or attaches a report (like a press release), it should be classified as a Regulatory Filing (RNS) rather than an Interim Report (IR) or Earnings Release (ER). The document is not a full earnings release but a Form 8-K current report announcing the earnings release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-05-09 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.